ライフサイエンスコーパス: desipramine

1 symptoms compared with patients assigned to desipramine.

2 symptoms (> or =40% reduction) compared with desipramine.

3 tentiated by the neuronal uptake-1 inhibitor desipramine.

4 SERT for the antidepressants paroxetine and desipramine.

5 3 tracers was inhibited by pretreatment with desipramine.

6 (n = 14) were treated on an open basis with desipramine.

7 ix months of a clinically determined dose of desipramine.

8 re blocked by cocaine and the antidepressant desipramine.

9 lacebo-treated alcoholics and can respond to desipramine.

10 ine, to the norepinephrine uptake inhibitor, desipramine.

11 complex with leucine and the antidepressant desipramine.

12 broblasts) with the tricyclic antidepressant desipramine (0.1-10 microM) in the presence or absence o

13 transporter (NET) inhibitors citalopram and desipramine (1 mg kg(-1) ).

14 ment with the tricyclic antidepressant (TCA) desipramine (10 mg/kg), the selective serotonin reuptake

15 antidepressants fluoxetine (5 mg/kg/day) and desipramine (10 mg/kg/day), and 3) forced swim test beha

16 erfusion was attenuated approximately 80% by desipramine (10 nmol/L) and 70% by 5-(N-ethyl-N-isopropy

17 selective norepinephrine uptake-1 inhibitor desipramine (2 mg/kg intravenously; n = 4), or saline co

18 Desipramine (2, 4, 8 micrograms/side), nisoxetine (2, 4,

19 Administration of desipramine (20 mg/kg, i.p.) 30 min prior to 6-OHDA inje

20 tested the hypothesis that administration of desipramine 200 mg prevents the state-related reduction

21 eks of the noradrenaline re-uptake inhibitor desipramine (5 mg/kg).

22 ceive 8 weeks of double-blind treatment with desipramine (50-200 mg/day) or fluoxetine (10-40 mg/day)

23 The antidepressants used were: desipramine (8 mg/kg, i.p., tricyclic), fluoxetine (8 mg

24 ertraline and fluoxetine) or norepinephrine (desipramine), a monoamine oxidase inhibitor (tranylcypro

25 norepinephrine selective reuptake inhibitor (desipramine), a serotonin selective reuptake inhibitor (

26 ermore, both palmitoyldihydrosphingosine and desipramine, a chemically and mechanically unrelated aci

27 The amphiphilic compound desipramine, a frequently employed inhibitor of acid sph

28 We report that both cocaine and desipramine, a potent NET inhibitor, failed to change DA

29 ith each tracer after oral administration of desipramine, a selective neuronal transport blocker.

30 tonin reuptake inhibitor, and active control desipramine, a selective norepinephrine reuptake inhibit

31 Desipramine abolished the normal reduction of geniogloss

32 Neither 6-OHDA nor desipramine altered striatal PDE4A or PDE4B isozymes.

33 of forebrain BDNF attenuates the actions of desipramine, an antidepressant, in the forced swim test,

34 n affinity for dopamine, a NET substrate, or desipramine, an inhibitor, at the expense of affinity fo

35 s known to inhibit mammalian ASM activities, desipramine and clomipramine, markedly extend the lifesp

36 nt with the neuronal amine-uptake inhibitors desipramine and cocaine, the alpha 1-adrenoceptor agonis

37 in the NAc increases the efficacy of the TCA desipramine and dramatically accelerates its onset of ac

38 uation, employing well-known antidepressants desipramine and fluoxetine as test compounds in dog and

39 of C6 glioma cells with the antidepressants desipramine and fluoxetine increases the Triton X-100 so

40 repeated treatment with the antidepressants desipramine and fluoxetine or the PDE4 inhibitor rolipra

41 After initial medication with desipramine and follow-up until response, patients under

42 On using desipramine and imipramine as "arbitrarily selected stan

43 Desipramine and imipramine, inhibitors of acid sphingomy

44 The antidepressants fluoxetine, desipramine and ketamine increased PKMzeta expression in

45 and 6 were increased by the antidepressants desipramine and mirtazapine.

46 pable of causing marked elevations in plasma desipramine and nortriptyline concentrations.

47 ne reinstated the behavioral effects of both desipramine and paroxetine in Dbh(-/-) mice, thus demons

48 gnificant differences between the adjunctive desipramine and placebo groups in obsessive-compulsive o

49 tatistically significant differences between desipramine and placebo in heart rate and blood pressure

50 on of ADHD symptoms between adults receiving desipramine and placebo.

51 more improved with sertraline compared with desipramine and placebo; the factors for mood (P<.001) a

52 ssants, including the NE reuptake inhibitors desipramine and reboxetine, the monoamine oxidase inhibi

53 jection, all three drugs tested: fluoxetine, desipramine and TCP decreased total BDNF mRNA (exon V) a

54 he P450 biotransformation of imipramine into desipramine and to determine the IC50 value of a chemica

55 e interaction of an antidepressant molecule, desipramine, and its location in the membrane.

56 ble for increased sensitivity to imipramine, desipramine, and nortriptyline.

57 s, apical uptake was inhibited by verapamil, desipramine, and quinidine, but not by MPP+ (1-methyl-4-

58 Long-term maintenance treatment with desipramine appeared to be effective in the prevention o

59 his study warrant careful reconsideration of desipramine as a specific inhibitor for ASMase.

60 placebo-controlled, parallel-design study of desipramine at a target daily dose of 200 mg in 41 adult

61 nally, the acidic sphingomyelinase inhibitor desipramine attenuated HDACI/perifosine-mediated ceramid

62 B variant in hypothalamus; administration of desipramine attenuated the 6-OHDA-induced down-regulatio

63 Pretreatment of rats with desipramine attenuated the 6-OHDA-induced down-regulatio

64 Importantly, desipramine belongs to a group of tricyclic antidepressa

65 he kinetics of cocaine, methylphenidate, and desipramine binding to SERT and DAT.

66 on human SERT and DAT indicate that both the desipramine-binding site and its inhibition mechanism ar

67 Desipramine binds at the inner end of the extracellular

68 Desipramine blocked 5,7-DHT-induced norepinephrine (NE)

69 ts indicate that, as previously reported for desipramine, both amitriptyline and fluoxetine increase

70 n with desipramine pretreatment, a 1.5 mg/kg desipramine chase administered 10 min after tracer injec

71 Additionally, a desipramine chase did not change the cardiac (123)I-MIBG

72 A desipramine chase increased (11)C-hydroxyephedrine washo

73 d heart-to-mediastinum ratio, 1.99 +/- 0.12 (desipramine chase) vs. 2.05 +/- 0.16 (controls), not sta

74 Amitriptyline, nortriptyline, desipramine, clomipramine, dothiepin, and sertraline wer

75 tidepressants: amitriptyline, nortriptyline, desipramine, clomipramine, doxepin, dothiepin, fluoxetin

76 as sensitive to the lysosomotropic inhibitor desipramine, co-fractionated with lysosomes, and migrate

77 airway collapsibility was also reduced with desipramine compared with placebo (-10.0 cm H2O [-15.2 t

78 phasic genioglossus activity was higher with desipramine compared with placebo.

79 repinephrine transporter (NET) blockade with desipramine confirmed specific neural uptake of (18)F-LM

80 Desipramine decreased norepinephrine uptake to near maxi

81 the monkey with the selective NET inhibitor, desipramine, decreased the specific binding for both [(1

82 We also found that the antidepressant desipramine decreases these neural and behavioral effect

83 al therapy (CBT) against education (EDU) and desipramine (DES) against placebo (PLA) in female patien

84 significantly more effective than placebo or desipramine; desipramine was not better than placebo (F2

85 betaA expression, but fluoxetine as well as desipramine did increase Smad2 phosphorylation in the fr

86 Whereas desipramine did not by itself elicit circulating HSPCs,

87 norepinephrine transporter (NET) inhibitor, desipramine, did not adversely affect adult behavior, su

88 Rats pretreated with desipramine (DMI) (to prevent norepinephrine depletion)

89 and the norepinephrine transporter inhibitor desipramine (DMI) 10 mg/kg IP to raise MPFC DA levels wi

90 r to those observed in WT mice after chronic desipramine (DMI) administration.

91 to study the effects of two antidepressants, desipramine (DMI) and fluoxetine (FLX), in behavioral, e

92 Zimelidine (ZMI) and desipramine (DMI) are monoamine uptake inhibitors which

93 Prolonged treatment with the antidepressant desipramine (DMI) decreased the expression of both trans

94 Desipramine (DMI) is an antidepressant classically chara

95 healthy male Wistar rats at baseline, after desipramine (DMI) pretreatment (DMI block), and with DMI

96 essant and norepinephrine reuptake inhibitor desipramine (DMI) strongly suppressed REM sleep in rats

97 e establish that both subchronic and chronic desipramine (DMI) treatments upregulate hypothalamic ICE

98 Therefore, we hypothesized that desipramine (DMI), a NET antagonist, could affect the se

99 Here, we demonstrate that desipramine (DMI), a norepinephrine reuptake inhibitor t

100 ith the norepinephrine transporter inhibitor desipramine (DMI), each of these quantitative measures d

101 ose or long-term (3 weeks) administration of desipramine (DMI), fluoxetine (FLU), and mianserin (MIA)

102 selective norepinephrine reuptake inhibitor desipramine (DMI), or the monoamine oxidase inhibitor ph

103 by determining the effect on cell binding of desipramine (DMI), ouabain, norepinephrine (NE), unlabel

104 Tricyclic antidepressants (TCAs), such as desipramine (DMI), which block norepinephrine transporte

105 tyrosine administration would potentiate the desipramine (DMI)-induced elevation of medial prefrontal

106 inephrine neuronal transporter blockade with desipramine (DMI).

107 er intravenous infusion of the NET inhibitor desipramine (DMI).

108 studied: (Group 1) control; (Group 2) 100 nM desipramine (DMI); (Group 3) 0.8 microM SKF550; (Group 4

109 , a selective serotonin uptake inhibitor) or desipramine (DMI, a selective noradrenaline uptake inhib

110 Five desipramine dose levels were used to establish a range o

111 Further investigations revealed that desipramine down-regulated acid ceramidase (AC), but not

112 of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipr

113 e of depression in patients who responded to desipramine during the acute and continuation phases.

114 RI) and a norepinephrine reuptake inhibitor, desipramine, effectively reduces obsessive-compulsive sy

115 tine and the norepinephrine uptake inhibitor desipramine failed to reverse the effects of TBZ, and hi

116 Compared with desipramine, fluoxetine treatment showed a more rapid re

117 ment of initial antidepressant prescription (desipramine, fluoxetine, or imipramine).

118 a continuation phase of open treatment with desipramine for 16 weeks.

119 Treatment with desipramine for 24-96 hr had no effect on the expression

120 that the selectivity of methylphenidate and desipramine for DAT and SERT, respectively, can be accou

121 primarily norepinephrine reuptake inhibitor desipramine for patients with concurrent OCD and MDD.

122 tine did not show statistical superiority to desipramine for the treatment of PTSD symptoms.

123 for the placebo group and 11% for the active desipramine group (chi 2 = 8.1, P = .004).

124 e sertraline group, 18 subjects (36%) in the desipramine group, and 16 subjects (29%) in the placebo

125 e and was characteristic of binding to NETs (desipramine > imipramine > citalopram).

126 myelin levels were not altered by 4-HPR, and desipramine had no effect on ceramide level, suggesting

127 moval of 5-HT but not noradrenaline, whereas desipramine had the reverse action.

128 ition, an acidic sphingomyelinase inhibitor, desipramine, had no effect on TNF-alpha/CHX-induced cell

129 Because the tricyclic anti-depressant desipramine has been found to be effective in treating A

130 o-controlled trial evaluated the efficacy of desipramine hydrochloride (0 or 150 mg/d) plus buprenorp

131 t the results of a long-term study comparing desipramine hydrochloride and placebo for maintenance th

132 mg daily, augmented by lithium carbonate or desipramine hydrochloride if necessary; others received

133 f the noradrenergic tricyclic antidepressant desipramine hydrochloride in the treatment of children a

134 were randomized to sertraline hydrochloride, desipramine hydrochloride, or placebo for 3 months of do

135 Importantly, desipramine, imipramine, and a third ASMase inhibitor, S

136 y measuring the inhibition of its binding by desipramine, imipramine, or citalopram.

137 standard solutions as well as imipramine and desipramine in fortified human plasma samples.

138 d by all drugs tested, with the exception of desipramine in hippocampus.

139 a, we investigated the NE reuptake inhibitor desipramine in HSPC mobilization.

140 Clomipramine was also superior to desipramine in improving functional disability.

141 Clomipramine was superior to desipramine in the acute treatment of body dysmorphic di

142 Clomipramine is more effective than desipramine in the treatment of body dysmorphic disorder

143 I (sertraline) and a non-SRI antidepressant (desipramine) in the treatment of OCD with concurrent MDD

144 Regardless of sex or opioid medication, desipramine increased opioid and cocaine abstinence more

145 nation of two entirely different mechanisms; desipramine increases hERG endocytosis and degradation a

146 ondary dendrites in CA1, with fluoxetine and desipramine increasing the number of secondary dendrites

147 lated net uptake rate constants K(i) tracked desipramine-induced reductions of available NET in a dos

148 us oocytes accumulate 5HT, and paroxetine or desipramine inhibit this uptake.

149 Desipramine inhibition (DMI) of uptake-1 resulted in a s

150 Here, we have studied in detail how desipramine inhibits hERG surface expression.

151 ren and adolescents with ADHD, indicate that desipramine is effective in the treatment of ADHD in adu

152 Desipramine may be a useful adjunctive medication in fac

153 ness, helplessness, and hopelessness, in the desipramine-mazindol but not in the fluoxetine-sertralin

154 Treatment with desipramine (mean total daily dose, 3.4 mg/kg per day) w

155 valuated by in vivo inhibition of the NET by desipramine (n = 6).

156 h either norepinephrine reuptake inhibitors (desipramine [n = 7] or mazindol [n = 2]) or serotonin re

157 : paroxetine+naltrexone; paroxetine+placebo; desipramine+naltrexone; desipramine+placebo.

158 c administration of the antidepressant drugs desipramine, nortryptiline and paroxetine (PAR) (10 mg/k

159 In a double-blind study, desipramine or placebo was added for 6 or 10 weeks to th

160 norepinephrine-specific re-uptake inhibitor (desipramine), or saline and killed after 24 h.

161 Desipramine- or fluoxetine-treated cells show a more cen

162 bstinent significantly longer when receiving desipramine (P=.03).

163 Desipramine partially attenuated the 6-OHDA-mediated dec

164 pendent manner (IC50 = 0.068 +/- 0.010 mg of desipramine per kilogram).

165 oncentration (IC50) of 0.087 +/- 0.012 mg of desipramine per kilogram.

166 paroxetine+placebo; desipramine+naltrexone; desipramine+placebo.

167 Higher desipramine plasma levels were associated with greater o

168 Desipramine plasma levels were determined at weeks 4 and

169 Desipramine plasma levels were higher in women than in m

170 Desipramine pretreatment markedly reduced (> 60%) myocar

171 der norepinephrine transport inhibition with desipramine pretreatment, a 1.5 mg/kg desipramine chase

172 re partially normalized to control values by desipramine pretreatment.

173 ere was preserved (18)F-LMI1195 uptake after desipramine pretreatment.

174 By directly locking the gate, desipramine prevents conformational changes and blocks s

175 Desipramine reduces the state-related drop in tonic geni

176 eatment with norbinaltorphimine, even though desipramine remained effective.

177 gle dose of 5 and 10 mg/kg for midazolam and desipramine, respectively.

178 on of the antidepressant drugs fluoxetine or desipramine restores learning in mice exposed to the abe

179 Fluoxetine and desipramine reversed lower, but not higher, stress-induc

180 ccumulation is Na(+)-, Cl(-)-, cocaine-, and desipramine-sensitive and temperature-dependent, and tha

181 e in MENX mut/mut rats could be inhibited by desipramine, shown by biodistribution studies (0.06 +/-

182 Desipramine significantly reduced core symptoms of ADHD

183 Likewise, desipramine significantly reduced tic symptoms (Yale Glo

184 e-effect curves were generated with cocaine, desipramine, SKF-38393, quinpirole, SCH-23390, and sulpi

185 cantly inhibited by phenoxybenzamine but not desipramine, suggesting (18)F-LMI1195 is a substrate for

186 the acid sphingomyelinase-inactivating drug, desipramine, synergize to reverse susceptibility, sugges

187 More patients receiving desipramine than sertraline discontinued treatment becau

188 gs (haloperidol, raclopride, sertraline, and desipramine) that lack reinforcing or sensitizing proper

189 lyzed following the normal administration of desipramine to a volunteer, and the parent drug was dete

190 and abdomen, with or without treatment with desipramine to block sympathoneural uptake of catecholam

191 Use of desipramine to reduce relapse in nondepressed alcoholics

192 treatment with paroxetine (to 60 mg/day) or desipramine (to 30 mg/day) in a 3-to-1 ratio, respective

193 Hamilton Depression scores of desipramine-treated depressed alcoholics decreased signi

194 Desipramine-treated depressed patients were more satisfi

195 Within the desipramine-treated group, there were clinically and sta

196 ct, predefined criteria for response, 68% of desipramine-treated subjects and no subjects in the plac

197 change in the distribution of Goalpha after desipramine treatment and the antipsychotic drug chlorpr

198 compared the effectiveness of fluoxetine and desipramine treatment in a prospective double-blind phar

199 ed patients then were randomized to continue desipramine treatment or tapered to placebo treatment fo

200 Desipramine treatment was associated with decreased 6-(1

201 Compared with desipramine treatment, fluoxetine treatment was associat

202 ine or S1P rescued PGE(2) biosynthesis after desipramine treatment.

203 kers such as bongkrekic acid, Nortriptyline, Desipramine, Trifluoperazine, and Maprotiline.

204 t with either sertraline (up to 200 mg/d) or desipramine (up to 300 mg/d) over 12 weeks.

205 he ADHD response rate was robust (71% vs 0%; desipramine vs placebo, P<.001).

206 ic response rate was substantial (58% vs 5%; desipramine vs placebo, P<.001).

207 Desipramine was found to (i) induce GR translocation fro

208 Response to desipramine was independent of dose, level of impairment

209 However, the action of desipramine was independent of its action on ASMase, sin

210 more effective than placebo or desipramine; desipramine was not better than placebo (F2,163 = 12.47,

211 However, desipramine was superior to paroxetine with respect to s

212 Desipramine was titrated weekly up to 3.5 mg/kg per day.

213 Treatment with desipramine was well tolerated and was associated with r

214 sant (fluoxetine) was employed if the first (desipramine) was either ineffective or poorly tolerated,

215 analyses of fortified samples of imipramine desipramine were measured relative to their correspondin